1347 GMT - The consumer-health industry could see more merger-and-acquisition activity, but smaller deals for certain brands or segments seem more likely than large-scale takeovers, Citi analysts say in a research note. Recent spinoffs such as Kenvue and Haleon, potential splits or asset reviews at Bayer and Reckitt Benckiser, and acquisition attempts like Unilever's for Haleon in 2022 left investors wondering whether the industry could consolidate, Citi says. Healthy balance sheets and interest from the likes of Procter & Gamble suggest there is room for acquisitions, but antitrust concerns and diverse portfolios make large deals unlikely, Citi says. In a large takeover, the buyer would probably need a significant portfolio reshaping afterward, the analysts say. The Stoxx Europe 600 Personal & Household Goods index is up 0.6%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 30, 2025 09:47 ET (13:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。